Welcome back to the channel. Welcome back to Plenary Session.

For those of you listening on the audio feed, I encourage you this one, you're going to want to jump on the video.

Get to YouTube, check this out on Vinay Prasad MDMPH, the channel.

And for those of you watching the video, you'll be glad you watched because I have a lot of visuals.

I'm going to talk about this study, the talk of the town, echelon one.

We finally have what has been long awaited the overall survival results for A-A-A-V-D versus A-B-V-D.

It's A-A-A-V-D that A is Ad-Cetrus or Brintuxemab-V-Oten.

It used to be A-B-V-D, and this is the trial that supposedly changed our practice.

It has huge financial

implications. It has huge implications for all of Hodgkin's lymphoma. And I'm going to break

down this paper. I have read this paper and poured through it for two to three hours, and I feel

like it's still not enough. It's still not enough. I want to do more, but a bunch of people who I admire have asked me to put the video out there,

put the video, tell me what you got so far.

So I'll tell you what I got so far, but I want to look at it even harder,

and I might do that in the future if I find something else.

Oh, the next thing, somebody asked me, if I listen to

plenary session or I listen to one of your videos and you make a good point and I want to use that

an article of mine, should I cite you? And the answer is, yes, of course, you should cite. I mean,

what are you talking about? Yeah, you shouldn't take an idea and pretend it's your own if you heard it somewhere else. So yes, of course, you cite a podcast just like can cite anything else.

That's a simple question.

Okay, here we go.

Overall survival with BV.

...